Is ANIX or LRMR more profitable?

Anixa Biosciences' return on equity of -71.12% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Larimar Therapeutics N/A -134.14% -96.00%

Does the media prefer ANIX or IRD?

In the previous week, Anixa Biosciences had 4 more articles in the media than Opus Genetics. MarketBeat recorded 12 mentions for Anixa Biosciences and 8 mentions for Opus Genetics. Anixa Biosciences' average media sentiment score of 1.38 beat Opus Genetics' score of 0.83 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Opus Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GLSI or ANIX more profitable?

Anixa Biosciences' return on equity of -71.12% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenwich LifeSciences N/A -941.15% -368.53% Anixa Biosciences N/A -71.12% -62.88%

Is ANIX or ZURA more profitable?

Zura Bio's return on equity of -55.74% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Zura Bio N/A -55.74% -48.07%

Does the media refer more to ANIX or ZURA?

In the previous week, Anixa Biosciences had 10 more articles in the media than Zura Bio. MarketBeat recorded 12 mentions for Anixa Biosciences and 2 mentions for Zura Bio. Anixa Biosciences' average media sentiment score of 1.38 beat Zura Bio's score of 0.45 indicating that Anixa Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zura Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anixa Biosciences (ANIX) Competitors

$2.47 0.00 (0.00%)

As of 06/12/2026 04:00 PM Eastern

Compare

ANIX vs. LRMR, IRD, ENTA, GLSI, and ZURA

Should you buy Anixa Biosciences stock or one of its competitors? MarketBeat compares Anixa Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anixa Biosciences include Larimar Therapeutics (LRMR), Opus Genetics (IRD), Enanta Pharmaceuticals (ENTA), Greenwich LifeSciences (GLSI), and Zura Bio (ZURA). These companies are all part of the "pharmaceutical products" industry.

How does Anixa Biosciences compare to Larimar Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Anixa Biosciences has higher revenue and earnings than Larimar Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	400.14	-$10.93M	-$0.31	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anixa Biosciences' return on equity of -71.12% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Larimar Therapeutics	N/A	-134.14%	-96.00%

In the previous week, Anixa Biosciences had 11 more articles in the media than Larimar Therapeutics. MarketBeat recorded 12 mentions for Anixa Biosciences and 1 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 1.87 beat Anixa Biosciences' score of 1.38 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Positive
Larimar Therapeutics	Very Positive

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 244.13%. Larimar Therapeutics has a consensus target price of $15.29, suggesting a potential upside of 340.51%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

Summary

Larimar Therapeutics beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to Opus Genetics?

Anixa Biosciences (NASDAQ:ANIX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Opus Genetics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by company insiders. Comparatively, 11.7% of Opus Genetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Anixa Biosciences has higher earnings, but lower revenue than Opus Genetics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	400.14	-$10.93M	-$0.31	N/A
Opus Genetics	$14.20M	23.49	-$49.59M	-$1.33	N/A

In the previous week, Anixa Biosciences had 4 more articles in the media than Opus Genetics. MarketBeat recorded 12 mentions for Anixa Biosciences and 8 mentions for Opus Genetics. Anixa Biosciences' average media sentiment score of 1.38 beat Opus Genetics' score of 0.83 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Opus Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences presently has a consensus price target of $8.50, suggesting a potential upside of 244.13%. Opus Genetics has a consensus price target of $10.67, suggesting a potential upside of 164.03%. Given Anixa Biosciences' higher probable upside, equities research analysts clearly believe Anixa Biosciences is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Anixa Biosciences has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Anixa Biosciences' return on equity of -71.12% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Opus Genetics	-892.36%	-338.88%	-191.21%

Summary

Anixa Biosciences beats Opus Genetics on 12 of the 17 factors compared between the two stocks.

How does Anixa Biosciences compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

Anixa Biosciences has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -89.56%. Enanta Pharmaceuticals' return on equity of -64.04% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Anixa Biosciences	N/A	-71.12%	-62.88%

Anixa Biosciences has lower revenue, but higher earnings than Enanta Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.30	-$81.89M	-$2.59	N/A
Anixa Biosciences	$210K	400.14	-$10.93M	-$0.31	N/A

Enanta Pharmaceuticals has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Enanta Pharmaceuticals currently has a consensus target price of $20.29, indicating a potential upside of 70.47%. Anixa Biosciences has a consensus target price of $8.50, indicating a potential upside of 244.13%. Given Anixa Biosciences' higher possible upside, analysts clearly believe Anixa Biosciences is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Anixa Biosciences had 11 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 12 mentions for Anixa Biosciences and 1 mentions for Enanta Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 1.87 beat Anixa Biosciences' score of 1.38 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Very Positive
Anixa Biosciences	Positive

Summary

Enanta Pharmaceuticals beats Anixa Biosciences on 9 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Greenwich LifeSciences?

Greenwich LifeSciences (NASDAQ:GLSI) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 51.5% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Anixa Biosciences had 11 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 12 mentions for Anixa Biosciences and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.87 beat Anixa Biosciences' score of 1.38 indicating that Greenwich LifeSciences is being referred to more favorably in the media.

Company	Overall Sentiment
Greenwich LifeSciences	Very Positive
Anixa Biosciences	Positive

Greenwich LifeSciences presently has a consensus price target of $47.50, indicating a potential upside of 97.42%. Anixa Biosciences has a consensus price target of $8.50, indicating a potential upside of 244.13%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anixa Biosciences' return on equity of -71.12% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenwich LifeSciences	N/A	-941.15%	-368.53%
Anixa Biosciences	N/A	-71.12%	-62.88%

Greenwich LifeSciences has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Anixa Biosciences has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A
Anixa Biosciences	$210K	400.14	-$10.93M	-$0.31	N/A

Summary

Anixa Biosciences beats Greenwich LifeSciences on 11 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Zura Bio?

Anixa Biosciences (NASDAQ:ANIX) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Anixa Biosciences has higher revenue and earnings than Zura Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	400.14	-$10.93M	-$0.31	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.09	N/A

In the previous week, Anixa Biosciences had 10 more articles in the media than Zura Bio. MarketBeat recorded 12 mentions for Anixa Biosciences and 2 mentions for Zura Bio. Anixa Biosciences' average media sentiment score of 1.38 beat Zura Bio's score of 0.45 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zura Bio's return on equity of -55.74% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Zura Bio	N/A	-55.74%	-48.07%

Anixa Biosciences has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Zura Bio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 244.13%. Zura Bio has a consensus target price of $10.75, indicating a potential upside of 190.54%. Given Anixa Biosciences' higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Zura Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 12.4% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Anixa Biosciences beats Zura Bio on 8 of the 14 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$84.03M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-7.97	20.00	24.00	24.42
Price / Sales	400.14	306.76	515.84	118.72
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	5.88	8.32	10.60	6.82
Net Income	-$10.93M	$23.94M	$3.57B	$337.56M
7 Day Performance	0.41%	1.84%	0.59%	1.16%
1 Month Performance	-12.41%	-0.04%	1.54%	3.16%
1 Year Performance	-26.05%	44.82%	25.41%	30.60%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	2.4699 of 5 stars	$2.47 flat	$8.50 +244.1%	-26.0%	$84.03M	$210K	N/A	5	News Coverage Positive News Earnings Report Analyst Forecast Analyst Revision
LRMR Larimar Therapeutics	3.6541 of 5 stars	$3.10 -2.2%	$15.29 +393.1%	+20.5%	$329.31M	N/A	N/A	30	Positive News Gap Up
IRD Opus Genetics	3.0836 of 5 stars	$4.03 flat	$10.67 +164.7%	+316.5%	$328.02M	$14.20M	N/A	14	Analyst Revision
ENTA Enanta Pharmaceuticals	1.9544 of 5 stars	$11.07 -1.9%	$20.29 +83.2%	+58.7%	$328M	$65.32M	N/A	160	Positive News Gap Down
GLSI Greenwich LifeSciences	1.8174 of 5 stars	$21.65 -2.7%	$47.50 +119.4%	+161.5%	$326.59M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. LRMR, IRD, ENTA, GLSI, and ZURA

How does Anixa Biosciences compare to Larimar Therapeutics?

Summary

How does Anixa Biosciences compare to Opus Genetics?

Summary

How does Anixa Biosciences compare to Enanta Pharmaceuticals?

Summary

How does Anixa Biosciences compare to Greenwich LifeSciences?

Summary

How does Anixa Biosciences compare to Zura Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. LRMR, IRD, ENTA, GLSI, and ZURA

How does Anixa Biosciences compare to Larimar Therapeutics?

Which has stronger earnings & valuation, ANIX or LRMR?

Do institutionals and insiders have more ownership in ANIX or LRMR?

Is ANIX or LRMR more profitable?

Does the media refer more to ANIX or LRMR?

Do analysts recommend ANIX or LRMR?

Which has more volatility and risk, ANIX or LRMR?

Summary

How does Anixa Biosciences compare to Opus Genetics?

Which has more risk and volatility, ANIX or IRD?

Do insiders and institutionals hold more shares of ANIX or IRD?

Which has higher valuation and earnings, ANIX or IRD?

Does the media prefer ANIX or IRD?

Do analysts rate ANIX or IRD?

Is ANIX or IRD more profitable?

Summary

How does Anixa Biosciences compare to Enanta Pharmaceuticals?

Is ENTA or ANIX more profitable?

Which has preferable valuation and earnings, ENTA or ANIX?

Which has more volatility & risk, ENTA or ANIX?

Do institutionals & insiders have more ownership in ENTA or ANIX?

Do analysts prefer ENTA or ANIX?

Does the media favor ENTA or ANIX?

Summary

How does Anixa Biosciences compare to Greenwich LifeSciences?

Do institutionals & insiders believe in GLSI or ANIX?

Does the media prefer GLSI or ANIX?

Do analysts prefer GLSI or ANIX?

Is GLSI or ANIX more profitable?

Which has more risk & volatility, GLSI or ANIX?

Which has stronger valuation & earnings, GLSI or ANIX?

Summary

How does Anixa Biosciences compare to Zura Bio?

Which has preferable valuation and earnings, ANIX or ZURA?

Does the media refer more to ANIX or ZURA?

Is ANIX or ZURA more profitable?

Which has more volatility & risk, ANIX or ZURA?

Do analysts prefer ANIX or ZURA?

Do insiders & institutionals have more ownership in ANIX or ZURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools